Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging

J. P. Dyke, D. Sondhi, H. U. Voss, D. C. Shungu, X. Mao, K. Yohay, S. Worgall, N. R. Hackett, C. Hollmann, M. E. Yeotsas, A. L. Jeong, B. Van de Graaf, I. Cao, S. M. Kaminsky, L. A. Heier, K. D. Rudser, M. M. Souweidane, M. G. Kaplitt, B. Kosofsky, Ronald CrystalD. Ballon

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE: LINCL is a uniformly fatal lysosomal storage disease resulting from mutations in the CLN2 gene that encodes for tripeptidyl peptidase 1, a lysosomal enzyme necessary for the degradation of products of cellular metabolism. With the goal of developing quantitative noninvasive imaging biomarkers sensitive to disease progression, we evaluated a 5-component MR imaging metric and tested its correlation with a clinically derived disease-severity score. MATERIALS AND METHODS: MR imaging parameters were measured across the brain, including quantitative measures of the ADC, FA, nuclear spin-spin relaxation times (T2), volume percentage of CSF (%CSF), and NAA/Cr ratios. Thirty MR imaging datasets were prospectively acquired from 23 subjects with LINCL (2.5- 8.4 years of age; 8 male/15 female). Whole-brain histograms were created, and the mode and mean values of the histograms were used to characterize disease severity. RESULTS: Correlation of single MR imaging parameters against the clinical disease-severity scale yielded linear regressions with R2 ranging from 0.25 to 0.70. Combinations of the 5 biomarkers were evaluated by using PCA. The best combination included ADC, %CSF, and NAA/Cr (R2 = 0.76, P < .001). CONCLUSIONS: The multiparametric disease-severity score obtained from the combination of ADC, %CSF, and NAA/Cr whole-brain MR imaging techniques provided a robust measure of disease severity, which may be useful in clinical therapeutic trials of LINCL in which an objective assessment of therapeutic response is desired.

Original languageEnglish
Pages (from-to)884-889
Number of pages6
JournalAmerican Journal of Neuroradiology
Volume34
Issue number4
DOIs
Publication statusPublished - 1 Apr 2013
Externally publishedYes

Fingerprint

Neuronal Ceroid-Lipofuscinoses
Biomarkers
Lysosomal Storage Diseases
Passive Cutaneous Anaphylaxis
Brain
Neuroimaging
Disease Progression
Linear Models
Clinical Trials
Mutation
Enzymes
Therapeutics
Genes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology

Cite this

Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging. / Dyke, J. P.; Sondhi, D.; Voss, H. U.; Shungu, D. C.; Mao, X.; Yohay, K.; Worgall, S.; Hackett, N. R.; Hollmann, C.; Yeotsas, M. E.; Jeong, A. L.; Van de Graaf, B.; Cao, I.; Kaminsky, S. M.; Heier, L. A.; Rudser, K. D.; Souweidane, M. M.; Kaplitt, M. G.; Kosofsky, B.; Crystal, Ronald; Ballon, D.

In: American Journal of Neuroradiology, Vol. 34, No. 4, 01.04.2013, p. 884-889.

Research output: Contribution to journalArticle

Dyke, JP, Sondhi, D, Voss, HU, Shungu, DC, Mao, X, Yohay, K, Worgall, S, Hackett, NR, Hollmann, C, Yeotsas, ME, Jeong, AL, Van de Graaf, B, Cao, I, Kaminsky, SM, Heier, LA, Rudser, KD, Souweidane, MM, Kaplitt, MG, Kosofsky, B, Crystal, R & Ballon, D 2013, 'Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging', American Journal of Neuroradiology, vol. 34, no. 4, pp. 884-889. https://doi.org/10.3174/ajnr.A3297
Dyke, J. P. ; Sondhi, D. ; Voss, H. U. ; Shungu, D. C. ; Mao, X. ; Yohay, K. ; Worgall, S. ; Hackett, N. R. ; Hollmann, C. ; Yeotsas, M. E. ; Jeong, A. L. ; Van de Graaf, B. ; Cao, I. ; Kaminsky, S. M. ; Heier, L. A. ; Rudser, K. D. ; Souweidane, M. M. ; Kaplitt, M. G. ; Kosofsky, B. ; Crystal, Ronald ; Ballon, D. / Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging. In: American Journal of Neuroradiology. 2013 ; Vol. 34, No. 4. pp. 884-889.
@article{7b3e125c2cce48a5b20fadbba22c206d,
title = "Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging",
abstract = "BACKGROUND AND PURPOSE: LINCL is a uniformly fatal lysosomal storage disease resulting from mutations in the CLN2 gene that encodes for tripeptidyl peptidase 1, a lysosomal enzyme necessary for the degradation of products of cellular metabolism. With the goal of developing quantitative noninvasive imaging biomarkers sensitive to disease progression, we evaluated a 5-component MR imaging metric and tested its correlation with a clinically derived disease-severity score. MATERIALS AND METHODS: MR imaging parameters were measured across the brain, including quantitative measures of the ADC, FA, nuclear spin-spin relaxation times (T2), volume percentage of CSF ({\%}CSF), and NAA/Cr ratios. Thirty MR imaging datasets were prospectively acquired from 23 subjects with LINCL (2.5- 8.4 years of age; 8 male/15 female). Whole-brain histograms were created, and the mode and mean values of the histograms were used to characterize disease severity. RESULTS: Correlation of single MR imaging parameters against the clinical disease-severity scale yielded linear regressions with R2 ranging from 0.25 to 0.70. Combinations of the 5 biomarkers were evaluated by using PCA. The best combination included ADC, {\%}CSF, and NAA/Cr (R2 = 0.76, P < .001). CONCLUSIONS: The multiparametric disease-severity score obtained from the combination of ADC, {\%}CSF, and NAA/Cr whole-brain MR imaging techniques provided a robust measure of disease severity, which may be useful in clinical therapeutic trials of LINCL in which an objective assessment of therapeutic response is desired.",
author = "Dyke, {J. P.} and D. Sondhi and Voss, {H. U.} and Shungu, {D. C.} and X. Mao and K. Yohay and S. Worgall and Hackett, {N. R.} and C. Hollmann and Yeotsas, {M. E.} and Jeong, {A. L.} and {Van de Graaf}, B. and I. Cao and Kaminsky, {S. M.} and Heier, {L. A.} and Rudser, {K. D.} and Souweidane, {M. M.} and Kaplitt, {M. G.} and B. Kosofsky and Ronald Crystal and D. Ballon",
year = "2013",
month = "4",
day = "1",
doi = "10.3174/ajnr.A3297",
language = "English",
volume = "34",
pages = "884--889",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "4",

}

TY - JOUR

T1 - Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging

AU - Dyke, J. P.

AU - Sondhi, D.

AU - Voss, H. U.

AU - Shungu, D. C.

AU - Mao, X.

AU - Yohay, K.

AU - Worgall, S.

AU - Hackett, N. R.

AU - Hollmann, C.

AU - Yeotsas, M. E.

AU - Jeong, A. L.

AU - Van de Graaf, B.

AU - Cao, I.

AU - Kaminsky, S. M.

AU - Heier, L. A.

AU - Rudser, K. D.

AU - Souweidane, M. M.

AU - Kaplitt, M. G.

AU - Kosofsky, B.

AU - Crystal, Ronald

AU - Ballon, D.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - BACKGROUND AND PURPOSE: LINCL is a uniformly fatal lysosomal storage disease resulting from mutations in the CLN2 gene that encodes for tripeptidyl peptidase 1, a lysosomal enzyme necessary for the degradation of products of cellular metabolism. With the goal of developing quantitative noninvasive imaging biomarkers sensitive to disease progression, we evaluated a 5-component MR imaging metric and tested its correlation with a clinically derived disease-severity score. MATERIALS AND METHODS: MR imaging parameters were measured across the brain, including quantitative measures of the ADC, FA, nuclear spin-spin relaxation times (T2), volume percentage of CSF (%CSF), and NAA/Cr ratios. Thirty MR imaging datasets were prospectively acquired from 23 subjects with LINCL (2.5- 8.4 years of age; 8 male/15 female). Whole-brain histograms were created, and the mode and mean values of the histograms were used to characterize disease severity. RESULTS: Correlation of single MR imaging parameters against the clinical disease-severity scale yielded linear regressions with R2 ranging from 0.25 to 0.70. Combinations of the 5 biomarkers were evaluated by using PCA. The best combination included ADC, %CSF, and NAA/Cr (R2 = 0.76, P < .001). CONCLUSIONS: The multiparametric disease-severity score obtained from the combination of ADC, %CSF, and NAA/Cr whole-brain MR imaging techniques provided a robust measure of disease severity, which may be useful in clinical therapeutic trials of LINCL in which an objective assessment of therapeutic response is desired.

AB - BACKGROUND AND PURPOSE: LINCL is a uniformly fatal lysosomal storage disease resulting from mutations in the CLN2 gene that encodes for tripeptidyl peptidase 1, a lysosomal enzyme necessary for the degradation of products of cellular metabolism. With the goal of developing quantitative noninvasive imaging biomarkers sensitive to disease progression, we evaluated a 5-component MR imaging metric and tested its correlation with a clinically derived disease-severity score. MATERIALS AND METHODS: MR imaging parameters were measured across the brain, including quantitative measures of the ADC, FA, nuclear spin-spin relaxation times (T2), volume percentage of CSF (%CSF), and NAA/Cr ratios. Thirty MR imaging datasets were prospectively acquired from 23 subjects with LINCL (2.5- 8.4 years of age; 8 male/15 female). Whole-brain histograms were created, and the mode and mean values of the histograms were used to characterize disease severity. RESULTS: Correlation of single MR imaging parameters against the clinical disease-severity scale yielded linear regressions with R2 ranging from 0.25 to 0.70. Combinations of the 5 biomarkers were evaluated by using PCA. The best combination included ADC, %CSF, and NAA/Cr (R2 = 0.76, P < .001). CONCLUSIONS: The multiparametric disease-severity score obtained from the combination of ADC, %CSF, and NAA/Cr whole-brain MR imaging techniques provided a robust measure of disease severity, which may be useful in clinical therapeutic trials of LINCL in which an objective assessment of therapeutic response is desired.

UR - http://www.scopus.com/inward/record.url?scp=84876705411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876705411&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A3297

DO - 10.3174/ajnr.A3297

M3 - Article

C2 - 23042927

AN - SCOPUS:84876705411

VL - 34

SP - 884

EP - 889

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 4

ER -